What Is Ampullary Cancer's 5-Year Survival by Stage?

When you are diagnosed with ampullary cancer (carcinoma of the ampulla of Vater), one of the first questions you likely have is about survival rates. A 5-year overall survival rate represents the percentage of people in a study group who are still alive five years after their diagnosis or surgery. It is important to understand that surviving five years does not necessarily mean the cancer never returned, and these statistics cannot predict your exact personal outcome.

Because ampullary cancer is rare, most detailed statistics come from studies of patients whose tumors were able to be surgically removed (resected). If your cancer cannot be removed with surgery, or if it has spread to distant organs (metastatic disease), your prognosis will be different from the numbers discussed below.

Survival Rates by Stage (Historical Benchmark)

Doctors currently use the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. However, exact published survival tables for the newest overall stage groupings are not yet widely available. Instead, doctors often look at data from a major international study of 841 patients who underwent surgery, which used the previous (AJCC 7th edition) staging rules ^[1]. Because the definitions of Stage II and III changed between editions, these older stage labels will not perfectly match a modern AJCC 8th edition pathology report, but they provide the clearest historical benchmark for what patients can generally expect after surgery:

• Stage IA: 80.3%
• Stage IB: 60.9%
• Stage IIA: 58.1%
• Stage IIB: 36.6%
• Stage III: 17.9%
• Stage IV: Not reliably estimable (Note: The study reported a 25.0% survival rate for Stage IV, but this was based on only four patients who had surgery despite advanced disease. This does not represent the typical experience for most patients with metastatic cancer) ^[1].

The Impact of Lymph Node Involvement

Under the current AJCC 8th edition rules, the extent of cancer in the lymph nodes (the “N” in your TNM stage) is one of the strongest predictors of survival ^[2]. This pathological stage can only be confirmed after surgery. Ampullary cancer is categorized by how many lymph nodes contain cancer cells:

• N0 (No lymph nodes involved): Patients with negative lymph nodes have the best prognosis. A validation study of 369 surgical patients using the newer staging rules found a 5-year overall survival rate of 44.8% for this group ^[2]. Other studies have shown rates over 60%, depending on the exact patient group evaluated and how many nodes were examined ^[3].
• N1 (1 to 3 positive lymph nodes): Survival rates drop when a few nodes are involved, with the validation study reporting a 20% 5-year overall survival rate ^[2].
• N2 (4 or more positive lymph nodes): Extensive lymph node involvement is associated with a much lower 5-year overall survival rate, measured at 4% in the same study ^[2].

The Importance of a Clear Margin (R0 Resection)

For patients who undergo surgery, the goal is an R0 resection. This means the pathologist examined the removed tissue and saw a “clear margin” of healthy tissue around the tumor, identifying no microscopic cancer cells at the edges. While achieving an R0 resection does not guarantee the cancer won’t return, it is associated with better long-term survival ^[4]. One study showed that the 5-year overall survival rate for patients with an R0 resection was nearly 70% (69.6%), compared to just 42.4% for those who had an R1 resection (where microscopic cancer cells are found at the very edge of the removed tissue) ^[4].

Tumor Subtype: Intestinal vs. Pancreatobiliary

Under a microscope, ampullary cancer cells generally look like they originated from either the intestines or the pancreas and bile ducts. This subtype distinction matters for your prognosis ^[5].

• Intestinal subtype: This type generally has a better prognosis. Studies evaluating patients after surgery have shown 5-year overall survival rates ranging from 61% to 72.8% for this subtype ^[4][5].
• Pancreatobiliary subtype: This type tends to be more aggressive, with 5-year overall survival rates typically ranging from 27.5% to 51.7% ^[4][5]. A large review of 23 studies (a meta-analysis) found that patients with the pancreatobiliary subtype had nearly double the risk of worse overall survival compared to those with the intestinal subtype ^[5]. However, it is important to know that pancreatobiliary tumors are also more likely to have other high-risk features—like positive lymph nodes and positive margins—which contributes heavily to these lower survival numbers ^[5].

Remember that these statistics are based on groups of people treated in the past. Your multidisciplinary care team will help you understand what your specific pathology results mean for your long-term plan.